A bivariate functional mapping model for identifying haplotypes that control drug response for systolic and diastolic blood pressures

Proceedings of the Pacific Symposium on Biocomputing 2006, PSB 2006

Volumn , Issue , 2006, Pages 572-583

  Lin, Min ^a   Wu, Rongling ^b   Johnson, Julie ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b University of Florida ^*  (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIVARIATE; BIVARIATE MODELS; CANDIDATE GENES; CURVE PARAMETERS; DOBUTAMINE; DRUG RESPONSE; ESTIMATION PROCESS; FUNCTIONAL MAPPING; GENETIC CONTROL; GENETIC MAKE-UP; GENETIC VARIANTS; HAPLOTYPE STRUCTURE; HAPLOTYPES; MATHEMATICAL ASPECTS; PERSONALIZED MEDICATIONS; RESPONSE CURVES; SEQUENCE VARIANTS; SINGLE NUCLEOTIDE POLYMORPHISMS; SYSTOLIC AND DIASTOLIC BLOOD PRESSURES;

BLOOD PRESSURE; DNA SEQUENCES;

GENES;

DNA;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; BIOLOGY; BLOOD PRESSURE; CHROMOSOME MAP; DIASTOLE; DRUG EFFECT; GENETIC VARIABILITY; GENETICS; HAPLOTYPE; HUMAN; METHODOLOGY; PHARMACOGENETICS; STATISTICAL MODEL; STATISTICS; SYSTOLE;

ALGORITHMS; BLOOD PRESSURE; CHROMOSOME MAPPING; COMPUTATIONAL BIOLOGY; DIASTOLE; DNA; HAPLOTYPES; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, GENETIC; MODELS, STATISTICAL; PHARMACOGENETICS; SYSTOLE; VARIATION (GENETICS);

EID: 39049179358     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (20)

1. W. E. Evans and M. V. Relling, Nature 429, 464 (2004).
2. J. Giraldo, Trends Pharmacolog. Sci. 24, 63 (2003).
3. C.-X. Ma, G. Casella and R. L. Wu, Genetics 161, 1751 (2002).
4. R. L. Wu, C.-X. Ma, M. Lin and G. Casella, Genetics 166, 1541 (2004).
5. R. L. Wu, C.-X. Ma, M. Lin, Z.-H. Wang and G. Casella, Biometrics 60, 729 (2004).
6. Y. Gong, Z. H. Wang, T. Liu, W. Zhao, Y. Zhu, J.A. Johnson and R.L. Wu, Pharmacogenomics J. 4, 315 (2004).
7. M. Lin, C. Aquilante, J. A. Johnson and R. L. Wu, Pharmacogenomics J. 5, 149 (2005).
8. M. Lin and R. L. Wu, Genetics 170, 919 (2005).
9. B.S. Weir, Sinauer, Sunderland, MA (1996).
10. P. J. Diggle, P. Heagerty, K. Y. Liang and S. L. Zeger, UK: Oxford University Press, (2002).
11. W. Zhao, R. L. Wu, C.-X. Ma and G. Casella, Genetics 167, 2133 (2004).
12. J. A. Nelder and R. Mead, Computer J. 7, 308 (1965).
13. G. A. Churchill and R. W. Doerge, Genetics 138, 963 (1994).
14. E. G. Nabel, N. Engl. J. Med. 349, 60 (2003).
15. J. A. Johnson and S. G. Terra, Pharmaceutical Res. 19, 1779 (2002).
16. J. A. Johnson and W. E. Evans, Trends Mol Med. 8, 300 (2002).
17. H. L. McLeod and J. Yu, Cancer Invest 21, 630 (2003).
18. W. Kalow, B. K. Tang and L. Endrenyi, Pharmacogenetics 8, 283 (1998).
19. The International HapMap Consortium, Nature 426, 789 (2003).
20. E. S. Lander and D. Botstein, Genetics 121, 185 (1989).